# Tasca Therapeutics

Source: https://onco.cc/companies/tasca-therapeutics/  
OnCo record `tasca-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Tasca Therapeutics makes pills that block cancer-driving proteins by plugging a pocket where the protein normally holds a fatty molecule. Its first medicine, CP-383, began its first human trial in advanced solid tumours in September 2025.

## Summary

Tasca Therapeutics is a clinical-stage company whose discovery platform identifies and maps lipid-binding pockets on proteins, including sites on auto-palmitoylated proteins, and designs small molecules against them. Its first-in-class lead, CP-383, is designed to modulate an oncogenic signalling pathway that the company has not named publicly; the launch release said it would first be evaluated in small cell lung, colorectal, head and neck and brain cancers. Tasca launched on 10 December 2024 with a USD 52 million Series A co-led by Regeneron Ventures and Cure Ventures with participation from the Invus Group, and on 16 September 2025 announced the first patient dosed in a phase 1/2 dose escalation and expansion trial of CP-383 in advanced solid tumours. Scientific founders are Xu Wu, David Fisher and Duojia Pan; co-founder Milenko Cicmil is chief executive.

## Fields

- Kind: Company
- Last checked: 2026-10-29
- HQ: Boston, MA
- Type: biotech
- Website: https://www.tascatx.com/

## Notes

- Founding year not stated; the site footer carries a 2022 copyright notice, which is not treated as a founding date. The pathway and protein that CP-383 acts on are not named on the company pages read, so no target is linked; no technology is linked because no technology record matches small molecules that bind lipid pockets, and the company does not describe its platform as AI-driven. The ClinicalTrials.gov number of the CP-383 trial was not stated on the release.

## Sources

- Official website: https://www.tascatx.com/
- Series A launch release, December 2024: https://www.tascatx.com/dec-10-press-release
- First patient dosed release, September 2025: https://www.tascatx.com/sept-18-press

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/), [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- fronts: [Drug Discovery Platforms](https://onco.cc/fronts/drug-discovery/), [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)

---
JSON: https://onco.cc/api/v1/entities/tasca-therapeutics.json